Cerebral Venous Thrombosis Treatment Guidelines

Introduction to Cerebral Venous Thrombosis

Cerebral venous thrombosis (CVT) accounts for 0.5-1% of all strokes, primarily affecting young individuals under 50 years of age 3
The American Heart Association recommends that CVT diagnosis requires neuroimaging, with MRI with MR venography being the preferred initial imaging modality 2

Diagnosis of CVT requires neuroimaging, with MRI with MR venography being the preferred initial imaging modality, as recommended by the American College of Radiology 2
CT venography can be used if MRI is not readily available in emergency settings, according to the American College of Emergency Physicians 2
Gradient echo T2 susceptibility-weighted images combined with MR venography can improve diagnostic accuracy, as stated by the American Heart Association 4
Catheter cerebral angiography may be necessary in patients with inconclusive CTV or MRV results but high clinical suspicion, as recommended by the Society of NeuroInterventional Surgery 4

Immediate anticoagulation should be started with either intravenous unfractionated heparin (UFH) or subcutaneous low-molecular-weight heparin (LMWH), as recommended by the American College of Cardiology 3, 2
The presence of intracerebral hemorrhage related to CVT is NOT a contraindication to anticoagulation, according to the American Heart Association 3, 2
Anticoagulation prevents thrombus propagation, increases recanalization, and reduces mortality and severe disability, as stated by the American College of Chest Physicians 1

All patients should be admitted to a stroke unit for close monitoring and specialized care, as recommended by the American Academy of Neurology 2
Management in a stroke unit optimizes care and minimizes complications, according to the American Heart Association 4

Confirm diagnosis with MRI/MRV or CT/CTV, as recommended by the American College of Radiology 2
Initiate anticoagulation with IV heparin or subcutaneous LMWH if no major contraindications, according to the American College of Cardiology 3, 1
For transient reversible risk factors: 3-6 months of oral anticoagulation, as recommended by the American Heart Association 3, 2
For idiopathic CVT or mild thrombophilia: 6-12 months, according to the American College of Chest Physicians 3, 2
For high-risk inherited thrombophilia or recurrent events: Consider indefinite (lifelong) anticoagulation, as stated by the American College of Cardiology 3, 2

The first episode of CVT in Behçet's Syndrome should be treated with high-dose glucocorticoids followed by tapering, as recommended by the European League Against Rheumatism 5
Anticoagulants may be added for a short duration in CVT patients with Behçet's Syndrome, according to the American College of Rheumatology 5
Seizures should be treated aggressively with antiepileptic medications, as stated by the American Academy of Neurology 3
For elevated intracranial pressure, treatments may include dexamethasone (4-8 mg/day oral or IV) for patients with significant white matter edema causing mass effect, as recommended by the American College of Emergency Physicians 1

A follow-up CTV or MRV at 3-6 months after diagnosis is reasonable to assess for recanalization of the occluded cortical vein/sinuses in stable patients, as recommended by the American College of Radiology 4
Early follow-up imaging is recommended in patients with persistent or evolving symptoms despite medical treatment, according to the American Heart Association 4
Diagnostic challenges include anatomic variants that may mimic sinus thrombosis, including sinus atresia/hypoplasia and asymmetrical sinus drainage, as stated by the American Society of Neuroradiology 6
Long-term use of dexamethasone (>3 weeks) is associated with significant toxicity and should be avoided, as recommended by the American College of Chest Physicians 1